Capricor Therapeutics Inc (NASDAQ:CAPR) Holdings Lowered by EAM Investors LLC

EAM Investors LLC lowered its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 45.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,276 shares of the biotechnology company's stock after selling 31,649 shares during the period. EAM Investors LLC owned approximately 0.08% of Capricor Therapeutics worth $528,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in CAPR. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares during the period. Russell Investments Group Ltd. boosted its holdings in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares during the period. AlphaQuest LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $78,000. New York State Common Retirement Fund raised its stake in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth $91,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CAPR shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright restated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Stock Down 1.2 %

NASDAQ CAPR traded down $0.17 during trading hours on Wednesday, hitting $13.72. The company had a trading volume of 881,516 shares, compared to its average volume of 1,484,480. The firm has a market cap of $626.69 million, a P/E ratio of -12.94 and a beta of 4.65. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a fifty day simple moving average of $12.24 and a 200-day simple moving average of $14.95.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Equities analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.